Protagonist Therapeutics Wolfe Research Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everybody. My name is Alex Hammond, and I'm the biopharma analyst here at Wolfe. It is my great pleasure to introduce Protagonist Therapeutics. We have Dinesh Patel, we have Sam, and Matthew. Thank you guys so much for joining us.
Our pleasure. It's been an absolutely fantastic year for Protagonist.
The icotibant launch has really been superb. As we think about it, how is it tracking relative to your own internal expectations, and how would you compare this to other IL-23 launches?
Yeah. I think, first and foremost, and by the way, thanks for inviting us. With icotibant, as you know, this product is an outcome of a partnership with J&J that started all the way back in 2017, and it's so great to see it come to fruition. First and foremost, I would acknowledge J&J is the best pharma partner a biotech could have. I mean, they are so insightful, so supportive, and the things they are doing with icotrokinra, we could just not have envisioned on our own, obviously. With icotrokinra, there is nothing but enthusiasm, whether you hear it from us or whether you hear it from the J&J executives. The script volumes are really very pleasing, and that's the number that's more than 1,000 words. The drug is approved for psoriasis, for psoriatic arthritis. The first study has been completed.
The primary endpoint has been met. For the other indications, in IBD, as you know, we have just amazing phase II UC data, and there is a good mechanistic rationale for that. Other indications will also pile up, and in J&J's words, also, this is one of the most upbeat launches they have seen in recent years, and this is one of the best drugs that could ever be. All the numbers and all the data and all the anecdotal evidence seems to be very supportive of such bold, bullish statements.
Yeah, true unicorn, right? Yeah.
Which is representative in the commercials as well.
It is unbelievable. Exactly. As we also think about the launch, J&J has been saying that 60% of patients are naive to therapy.
Where do you expect that to reach steady state, and where are these patients coming from currently?
When they say 60% of the patients are systemic naive, my translation is that these are the patients who are sort of like on very generic topical drugs, so to speak. These are kind of the new pool of patients to, quote-unquote, "targeted therapy," and it is great to see them being the recipients of icotrokinra, right? It kind of then brings icotrokinra into the category of first-line therapy, and that is the most optimal position one would like to have for such a great drug with a proven mechanism, but yet with the scarcity or rarity of being the only oral drug.
How important do you see direct-to-consumer to kind of activate that patient population, and do you think patients understand that clinical data, or do you think it is more so the ease of use that is very important here?
It could be a combination of things. The direct-to-consumer kind of attentiveness is important. We like the ads we are seeing and stuff like that, and so do our friends and family. It has certainly brought more awareness about the drug. It is very unique in a way, right? It is a drug of its kind. I think that kind of increasing the awareness is probably the right thing to do.
I think the DTC ads have been very important. Psoriasis, SKYRIZI and TREMFYA lately have been fighting month-over-month for who spends the most money in terms of advertising in the pharmaceutical marketplace. I would also say that generally, people underestimate the importance of safety in these kind of treatment choices. Psoriasis is the kind of a disease where you could make different kinds of choices. It's not immediately life-threatening and that sort of thing. It's been great to see that people really wanted to have a really safe oral choice. I mean, this is indicated, you could see how the SOTYKTU launch did when it was only up against OTEZLA, and there was no icotrokinra at that time, and it didn't meet expectations. I would argue that was largely because of the safety data.
Yeah. The other thing is, like, I mean, in terms of the advertisement, that kind of thing, this is the only ad where I am noticing they are claiming placebo-like safety in the ad itself, which is very unique. Even people who are not in the field of science will be noticing that. Safety is of paramount importance, and especially for chronic indications where you're going to take the drug for a long period of time.
Yeah, that's a great point. Thank you. We also got some ICONIC-ASCEND data last week. Can you walk us through what was shown and what the importance of that data is?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
